- Oops!Something went wrong.Please try again later.
Axcella Health Inc. AXLA was a big mover last session, as the company saw its shares rises more than 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $4.2 –$5.11 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Axcella Health. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Axcella Health currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is negative.
Axcella Health Inc. Price
Axcella Health Inc. price | Axcella Health Inc. Quote
Other top-ranked stock in the Medical - Biomedical and Genetics industry is 89BIO INC ETNB, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axcella Health Inc. (AXLA) : Free Stock Analysis Report
89BIO INC (ETNB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research